Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ATP4A | P20648 | 1/20 | 0.33 |
| ▸ | ATP4B | P51164 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 3/20 | 0.33 |
| ▸ | SLC8A1 | P32418 | 6/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4662902 | 1.00 | RIPK1 (0.36) | RIPK1RAB9AATP4AATP4BBRD4 | |
| SCHEMBL4663156 | 1.00 | RIPK1 (0.36) | RIPK1RAB9AATP4AATP4BBRD4 | |
| SCHEMBL2689410 | 0.92 | NPC1 (0.31) | RAB9A | |
| SCHEMBL4964561 | 0.91 | HRH3 (0.34) | RIPK1BRD4KDM4E | |
| SCHEMBL4961323 | 0.91 | HTR7 (0.31) | SLC8A1KDM4E | |
| SCHEMBL6020045 | 0.90 | DHODH (0.36) | RAB9AATP4AATP4BSLC8A1DHODH | |
| SCHEMBL4663178 | 0.90 | DHODH (0.36) | RAB9AATP4AATP4BSLC8A1DHODH | |
| SCHEMBL6019450 | 0.90 | DHODH (0.36) | RAB9AATP4AATP4BSLC8A1DHODH | |
| Hydrochloric Acid SCHEMBL5102503 | 0.90 | HRH3 (0.33) | KDM4E | |
| Hydrochloric Acid SCHEMBL5116944 | 0.90 | HTR7 (0.31) | SLC8A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113963-A1 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2008-05-15 | — | — | US | disclosed |
| EP-1863820-A1 | THIOAMIDE-SUBSTITUTED TRICYCLIC BENZIMIDAZOLES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | Nycomed GmbH (DE) | 2007-12-12 | — | — | EP | disclosed |
| US-7307084-B2 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2007-12-11 | — | — | US | disclosed |
| WO-2006100255-A1 | THIOAMIDE-SUBSTITUTED TRICYCLIC BENZIMIDAZOLES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | NYCOMED GMBH (DE) | 2006-09-28 | — | — | WO | disclosed |
| US-20060194968-A1 | Cyclic benizimidazoles | ALTANA PHARMA AG (DE) | 2006-08-31 | — | — | US | disclosed |
| EP-1613626-A1 | CYCLIC BENZIMIDAZOLES | ALTANA Pharma AG (DE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087701-A1 | CYCLIC BENZIMIDAZOLES | ALTANA PHARMA AG (DE) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194968-A1 | Cyclic benizimidazoles | VIP, SI, GIPR | RIPK1 4446/4885RAB9A 4475/4885ATP4A 417/4885 |
| US-20080113963-A1 | Cyclic benzimidazoles | VIP, GIPR, SI | RIPK1 4185/4885RAB9A 2004/4885ATP4A 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.